Drug Approval | October 18, 2021
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Equity raise to finance growth and investments in the biological space
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
Subscribe To Our Newsletter & Stay Updated
